

American Academy of Pediatrics



DEDICATED TO THE HEALTH OF ALL CHILDREN®

Disclosure of Commercial Support for AAP CME Activities

The AAP gratefully acknowledges support for the 2024 National Conference & Exhibition. The full list of supporters can be found here: <https://aapexperience.org/education-supporters/>

Disclosure of Financial Relationships and Mitigation of Conflicts of Interest for AAP CME Activities Grid

The AAP recognizes that there are a variety of financial relationships between individuals and ineligible companies that require review to identify possible conflicts of interest in a CME activity. The "AAP Policy on Disclosure of Financial Relationships and Mitigation of Conflicts of Interest for AAP CME Activities" is designed to ensure quality, objective, balanced, and scientifically rigorous AAP CME activities by identifying and mitigating all potential conflicts of interest prior to the confirmation of service of those in a position to influence and/or control CME content. AAP has taken steps to mitigate any potential conflicts of interest. The purpose of this policy is to ensure all potential conflicts of interest are identified and mechanisms to mitigate them prior to the CME activity are implemented in ways that are consistent with the public good. The AAP is committed to providing learners with commercially unbiased CME activities.

All AAP CME activities will strictly adhere to the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. In accordance with these Standards, the following decisions will be made free of the control of an ineligible company: identification of CME needs, determination of educational objectives, selection and presentation of content, selection of all persons and organizations that will be in a position to control the content, selection of educational methods, and evaluation of the CME activity.

DISCLOSURE OF FINANCIAL RELATIONSHIPS

All individuals in a position to influence and/or control the content of AAP CME activities are required to disclose to the AAP and subsequently to learners that the individual either has no financial relationships or any financial relationships with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in CME activities. An ineligible company is defined as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Listed below are the disclosures provided by individuals in a position to influence and/or control CME activity content. **All of the relevant financial relationships listed for these individuals have been mitigated.** *This activity may discuss or demonstrate pharmaceuticals and/or medical devices that are not approved by the FDA and/or medical or surgical procedures that involve an unapproved or "off-label" use of an approved device or pharmaceutical.*

All other faculty, planners and staff have reported no financial relationships with ineligible companies.

Name	Role	Any Financial Relationships (Please indicate Yes or No)	Name of Ineligible Company* Please list name(s) of entity AND Nature of Financial Relationship(s) (Please list: Research Grant, Speaker's Bureau, Stock/Bonds excluding mutual funds, Consultant, Other - identify)
Abdel-Rahman, Susan	Co-Author	Yes	Abbott: Advisory Board Member; Advantage Silver Dental Arrest LLC: Consultant
Anari, Jason	Senior Author	Yes	DePuy, A Johnson & Johnson Company; Speakers Bureau
Anderson, William	Faculty	Yes	Sanofi: Advisory Board Member; Regeneron: Advisory Board Member; Genentech: Advisory Board Member
Andras, Lindsay	Faculty	Yes	Medtronic: Consultant; Nuvasive: Consultant; Eli Lilly: Stockholder; Orthopediatrics: Consultant
Arbogast, Kristy	Senior Author	Yes	Oculogica: Research Grant
Armin, Samira	Faculty	Yes	Sanofi: Independent Contractor; Pampers: Independent Contractor; Aveeno: Advisory member; Buzzrx: Consultant; Vanicream: Consultant; Kabrita: Advisory Board member; Milk PEPP: Consultant; Nozebot: Consultant; GMAC: Consultant
Ayaz, Hasan	Co-Author	Yes	fNIR Devices, LLC: Stockholder; Infrascan Inc: Stockholder
Bachmann, Keith	Senior Author	Yes	Depuy Synthes Spine: Consultant; Stryker Spine: Consultant
Bain, Lisa	Abstract Reviewer	Yes	Delfina: Advisory Board Member
Ball, Lauren	Teaching Assistant	Yes	Vitalograph Inc: Employee/Owner; Respitech Medical Inc: Employee/Owner

DISCLOSURE OF FINANCIAL RELATIONSHIPS

All individuals in a position to influence and/or control the content of AAP CME activities are required to disclose to the AAP and subsequently to learners that the individual either has no financial relationships or any financial relationships with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in CME activities. An ineligible company is defined as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Listed below are the disclosures provided by individuals in a position to influence and/or control CME activity content. **All of the relevant financial relationships listed for these individuals have been mitigated.** This activity may discuss or demonstrate pharmaceuticals and/or medical devices that are not approved by the FDA and/or medical or surgical procedures that involve an unapproved or "off-label" use of an approved device or pharmaceutical.

All other faculty, planners and staff have reported no financial relationships with ineligible companies.

Name	Role	Any Financial Relationships (Please indicate Yes or No)	Name of Ineligible Company* Please list name(s) of entity AND Nature of Financial Relationship(s) (Please list: Research Grant, Speaker's Bureau, Stock/Bonds excluding mutual funds, Consultant, Other - identify)
Barnett, Elizabeth	Faculty	Yes	Sobi: Consultant; Pfizer: Principal Investigator; GSK: Principal Investigator
Barry, Jim	Abstract Reviewer	Yes	Aerogen Inc: Principal Investigator
Beam, Kristyn	Faculty	Yes	Chiesi Pharmaceuticals: Research Grant
Berkenbosch, John	Abstract Reviewer	Yes	Medtronic: Consultant; Purdu Pharma: Consultant
Berlan, Elise	Abstract Reviewer	Yes	Bayer: Advisory Board Member; Organon: Nexplanon clinical trainer and Research Grant
Bhatia, Rajeev	AAP Section/Council Program Chair	Yes	Merck Manual: Consultant
Bird, Andrew	Moderator	Yes	DBV Technologies: Consultant; Genentech: Consultant, Research Grant; Hanimmune Therapeutics: Consultant; Infanant Health: Independent Study Monitor; Novartis: Consultant; Parexel: Consultant; Aimimmune Therapeutics: Independent Contractor; Solta: Independent Contractor
Bocchini, Claire	Co-Author	Yes	Pfizer: Consultant
Bouton, Daniel	Co-Author	Yes	Medtronic: Consultant
Braham, Sabrina	Faculty	Yes	Coral Care: Advisory Board Member; Insite Health: Advisory Board Member; Silicon Valley Therapeutics: Advisory Board Member; Wellio.Health: Employee/Owner
Branco, Nelson	Faculty	Yes	Otonexus Medical Technologies: Consultant
Brooks, Jaysson	Co-Author	Yes	OrthoPediatrics: Consultant
Brown, Rebecca	Co-Author	Yes	Atricure: Consultant
Bryant, Kristina	Faculty	Yes	Pfizer: Principal Investigator; Enanta: Principal Investigator; Gilead: Principal Investigator
Burnette, W. Bryan	Co-Author	Yes	FibroGen, Inc.: Principal Investigator; PTC Therapeutics: Advisory Board Member
Campbell, James	Faculty	Yes	Merck: Consultant; Moderna: Consultant; GSK: Consultant; Sanofi: Consultant; Pfizer: Consultant
Chaffee, Tonya	Planning Group	Yes	Organanon: Honorarium; Hologic: Consultant
Chang, Todd	Faculty	Yes	i3Simulations, Inc.: Advisory Board Member
Chen, Clifford	Abstract Reviewer	Yes	Pieces tech: Consultant
Chung, Richard	Abstract Reviewer	Yes	Merck & Co., Inc.: Consultant
Clayton, Douglass	Faculty	Yes	Eli Lilly: Stockholder; Bristol Meyers Squibb: Stockholder
Coleman, Nailah	Abstract Reviewer	Yes	GoodSport, LLC: Advisory Board Member
Cotton, Bryan	Co-Author	Yes	Haemonetics: Advisory Board Member

DISCLOSURE OF FINANCIAL RELATIONSHIPS

All individuals in a position to influence and/or control the content of AAP CME activities are required to disclose to the AAP and subsequently to learners that the individual either has no financial relationships or any financial relationships with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in CME activities. An ineligible company is defined as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Listed below are the disclosures provided by individuals in a position to influence and/or control CME activity content. **All of the relevant financial relationships listed for these individuals have been mitigated.** This activity may discuss or demonstrate pharmaceuticals and/or medical devices that are not approved by the FDA and/or medical or surgical procedures that involve an unapproved or "off-label" use of an approved device or pharmaceutical.

All other faculty, planners and staff have reported no financial relationships with ineligible companies.

Name	Role	Any Financial Relationships (Please indicate Yes or No)	Name of Ineligible Company* Please list name(s) of entity AND Nature of Financial Relationship(s) (Please list: Research Grant, Speaker's Bureau, Stock/Bonds excluding mutual funds, Consultant, Other - identify)
Cox, Charles	Co-Author	Yes	Coagulex, Inc.: Advisory Board Member, Principal Investigator
Craig, Clifford	Abstract Reviewer	Yes	Johnson & Johnson: Stockholder
Cruz, Andrea	Faculty	Yes	Pfizer: Research Grant
Daniels, Alan	Co-Author	Yes	Atec: Consultant, Medtronic: Consultant, Orthofix: Consultant, Spineart: Consultant, Stryker: Consultant
Darrow, David	Teaching Assistant	Yes	Pierre Fabre Dermatologie: Speaker Bureau
Davis, Alexis	AAP Section/Council Program Chair	Yes	Lansing, Inc: Advisory Board Member
deJesus-Gonzalez, Nilka	Co-Author, Abstract Reviewer	Yes	Mallinckrodt Phamaceutical: Speaker Bureau, Natera: Speaker Bureau
De La Uz, Caridad	Moderator	Yes	Solid Biosciences: Advisory Board Member; AltaThera: Advisory Board Member
Decker, Jamie	Faculty	Yes	AltaThera: Advisory Board Member; Mezzion Pharma Co: Principal Investigator
Detterich, Jon	Co-Author	Yes	Alcor Scientific: Advisory Board Member, Research Grant
DiGiacomo, Daniel	Abstract Reviewer	Yes	Pfizer: Research Grant
Di Lorenzo, Carlo	AAP Section/Council Program Chair	Yes	Abbvie-Ironwood: Consultant; NeurAxis: Consultant; Takeda: Consultant; QOL, Inc: Consultant
Duggan, Christopher	Co-Author	Yes	Takeda: Research Grant
Dukhovny, Dmitry	Abstract Reviewer	Yes	Cheisi: Consultant
El Feghaly, Rana	Faculty	Yes	Merck: Research Grant
Ellis, Henry	Co-Author	Yes	Arthrex: Educational Support; Orthopaediatrics: Speaker Bureau; Smith & Nephew: Consultant
Emerson, Beth	Abstract Reviewer	Yes	Biohaven: Employee/Owner, Pfizer: Employee/Owner
Erickson, Elizabeth	Abstract Reviewer	Yes	DynaMed: Consultant

DISCLOSURE OF FINANCIAL RELATIONSHIPS

All individuals in a position to influence and/or control the content of AAP CME activities are required to disclose to the AAP and subsequently to learners that the individual either has no financial relationships or any financial relationships with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in CME activities. An ineligible company is defined as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Listed below are the disclosures provided by individuals in a position to influence and/or control CME activity content. **All of the relevant financial relationships listed for these individuals have been mitigated.** This activity may discuss or demonstrate pharmaceuticals and/or medical devices that are not approved by the FDA and/or medical or surgical procedures that involve an unapproved or "off-label" use of an approved device or pharmaceutical.

All other faculty, planners and staff have reported no financial relationships with ineligible companies.

Name	Role	Any Financial Relationships (Please indicate Yes or No)	Name of Ineligible Company* Please list name(s) of entity AND Nature of Financial Relationship(s) (Please list: Research Grant, Speaker's Bureau, Stock/Bonds excluding mutual funds, Consultant, Other - identify)
Espinosa, Claudia	Faculty	Yes	AstraZeneca: Principal Investigator; Merck: Principal Investigator; Enanta: Principal Investigator; Clinetic: Principal Investigator; Jansen and Jansen: Advisory Board Member
Fang, Jennifer	Abstract Reviewer	Yes	Teladoc Health: Stockholder
Flores, Anthony	Faculty	Yes	GlycosBio, Inc: Research Grant
Florin, Todd	Abstract Reviewer	Yes	Diasorin: Panelist
Flynn, John	Co-Author	Yes	Biomet: Independent Contractor
Foglia, Elizabeth	Faculty	Yes	Chiesi USA: Research grant, Consultant; Medtronic: Consultant
Fornari, Eric	Co-Author	Yes	GE Healthcare: Consultant
Fox, Claudia	Faculty	Yes	Novo Nordisk: Contractor; Eli Lilly: Contractor
Frischer, Jason	Co-Author	Yes	Takeda: Advisory Board Member
Fuchs, George	Faculty	Yes	Moderna: Research Grant
Fuchs, Molly	Moderator	Yes	Urovant/Syneos Health: Consultant
Fuerch, Janene	Teaching Assistant	Yes	EMME: Board of Directors; EmpoHealth: Advisory Board Member; Keriton: Consultant; Ceribell: Consultant; Laborie: Consultant; Novonate: Advisory Board Member; Gabi Smart Care: Board of Directors; Vitara: Consultant; Avanos: Consultant
Ganley, Theodore	Co-Author	Yes	AlloSource: Research Grant; Arthrex: Research Grant; Paladin Technology Solutions: Research Grant; Vericel Corporation: Principal Investigator, Vericel Corporation: Research Grant
Gertz, Shira Jolene	Abstract Reviewer	Yes	Abbott Labs: Stockholder; CVS: Stockholder
Golombek, Sergio	Abstract Reviewer	Yes	Prolacta: Speaker Bureau
Greiner, Mary	Abstract Reviewer	Yes	Cordata: Consultant
Gribben, Valerie	Abstract Reviewer	Yes	Doximity: Stockholder
Gross, Robert	Faculty	Yes	Rebion: Stockholder
Gudausky, Todd	Co-Author	Yes	Abbott Laboratory: Independent Contractor
Guglani, Lokesh	Faculty	Yes	Microbion Biosciences: Consultant
Gupta, Malika	Faculty	Yes	Alerje, Inc.: Advisory Board Member
Gupta, Rupal	Abstract Reviewer	Yes	Kyruus Health, Inc.: Clinical Services Director, Stockholder

DISCLOSURE OF FINANCIAL RELATIONSHIPS

All individuals in a position to influence and/or control the content of AAP CME activities are required to disclose to the AAP and subsequently to learners that the individual either has no financial relationships or any financial relationships with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in CME activities. An ineligible company is defined as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Listed below are the disclosures provided by individuals in a position to influence and/or control CME activity content. **All of the relevant financial relationships listed for these individuals have been mitigated.** This activity may discuss or demonstrate pharmaceuticals and/or medical devices that are not approved by the FDA and/or medical or surgical procedures that involve an unapproved or "off-label" use of an approved device or pharmaceutical.

All other faculty, planners and staff have reported no financial relationships with ineligible companies.

Name	Role	Any Financial Relationships (Please indicate Yes or No)	Name of Ineligible Company* Please list name(s) of entity AND Nature of Financial Relationship(s) (Please list: Research Grant, Speaker's Bureau, Stock/Bonds excluding mutual funds, Consultant, Other - identify)
Gura, Kathleen	Co-Author	Yes	Alcresta: Consultant Baxter: Advisory Board Member; Fresenius Kabi: Consultant; NorthSea Therapeutics: Consultant; Otsuka: Consultant; Takeda: Consultant
Gwynn, Lisa	Faculty, Abstract Reviewer	Yes	Merck: Advisory Board Member
Hamling, Alexander	Abstract Reviewer	Yes	Merck: Consultant
Hammitt, Laura	Faculty	Yes	Merck: Research Grant; AstraZeneca: Research Grant
Hariharan, Arun	Co-Author	Yes	Biedermann Motec: Consultant
Harris, Christopher	Abstract Reviewer	Yes	Enanta Pharmaceuticals: Employee/Owner, Stockholder; Vertex Pharmaceuticals: Stockholder
Healy, Helen	Abstract Reviewer	Yes	Aerogen Pharma: Consultant, Principal Investigator; Airway Therapeutics: Principal Investigator; Chiesi USA: Principal Investigator
Hippe, Daniel	Co-Author	Yes	GE Healthcare: Research Grant
Hogan, Angela	Planning Group	Yes	GlaxoSmithKline: Speaker Bureau
Hogue, Grant	Faculty	Yes	Medtronic: Consultant
Hubbard, Dena	Faculty, Abstract Reviewer	Yes	Abbott Nutrition: Speaker Bureau
Hudak, Mark	Abstract Reviewer	Yes	Aerogen LLC: Advisory Board Member, Principal Investigator; IBT Inc.: Advisory Board Member
Hudson, Jeff	Staff	Yes	CVS: Stockholder
Humiston, Sharon	Co-Author	Yes	Sanofi: Consultant, Sanofi: Speaker Bureau
Hunter, Brandon	Faculty, Abstract Reviewer	Yes	XN Health: Advisory Board Member; DM1 LLC: Advisory Board Member; KidTech: Advisory Board Member
Jatana, Kris	Faculty	Yes	Marpac Inc.: Royalties; Zotarix LLC: Shareholder; Landsdowne Labs LLC: Stockholder; Tivic Health Systems: Stockholder; Grace Medical: Royalties
Jeewa, Aamir	Faculty	Yes	Ultragenyx: Advisory Board Member; Abbott Industries: Research Grant; Merck: Advisory Board Member; Berlin Heart: Clinical Events Committee Chair
Johnson, Megan	Abstract Reviewer	Yes	Nuvasive: Consultant
Kahn, Mani	Senior Author	Yes	General Electric: Consultant; Johnson and Johnson: Consultant
Kaushal, Neil	Co-Author	Yes	Stryker Spine Corporation: Consultant

DISCLOSURE OF FINANCIAL RELATIONSHIPS

All individuals in a position to influence and/or control the content of AAP CME activities are required to disclose to the AAP and subsequently to learners that the individual either has no financial relationships or any financial relationships with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in CME activities. An ineligible company is defined as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Listed below are the disclosures provided by individuals in a position to influence and/or control CME activity content. **All of the relevant financial relationships listed for these individuals have been mitigated.** This activity may discuss or demonstrate pharmaceuticals and/or medical devices that are not approved by the FDA and/or medical or surgical procedures that involve an unapproved or "off-label" use of an approved device or pharmaceutical.

All other faculty, planners and staff have reported no financial relationships with ineligible companies.

Name	Role	Any Financial Relationships (Please indicate Yes or No)	Name of Ineligible Company* Please list name(s) of entity AND Nature of Financial Relationship(s) (Please list: Research Grant, Speaker's Bureau, Stock/Bonds excluding mutual funds, Consultant, Other - identify)
Khalil, Paul	Faculty	Yes	Exo Iris: Contractor
Kim, Young-Jo	Co-Author	Yes	Cytex Imagen: Stockholder
Kirsch, Andrew	Faculty	Yes	Palette Life Science: Consultant; Intuitive Surgical: Speaker Bureau; Global Continencc Inc: Employee/Owner
Klein, Bruce	Co-Author	Yes	Johnson & Johnson: Stockholder
Kwon, Soo	Abstract Reviewer	Yes	KidTech: Consultant
Lau, May	Faculty, Abstract Reviewer	Yes	Trainer: Nexplanon trainer
Lee, Brendan	Co-Author	Yes	Biomarin: Consultant; GQ Biotherapeutics: Licensor; Pacira: Licensor; Sanofi: Licensor; Zevra Therapeutics: Licensor
Lee-Kim, YoungNa	Faculty	Yes	Sanofi Pharmaceutical: Advisory Board Member
Leeds, Stephanie	Faculty	Yes	Regeneron, Inc.: Consultant; Linical, Inc.: Consultant
Leitch, Kellie	Abstract Reviewer	Yes	Johnson & Johnson: Speaker Bureau
Levy, Matthew	Co-Author	Yes	Cresilon, Inc: Consultant; Stryker Medical Education: Consultant, Speaker Bureau
Lewis, Dalila	Planning Group	Yes	Neurelis: Speaker Bureau
Li, Ying	Senior Author	Yes	Medtronic: Advisory Board Member
Liu, Raymond	Senior Author	Yes	Orthopediatrics: Royalties
Lobaugh, Lauren	Abstract Reviewer	Yes	Omniceil: Consultant
Lohr, Jami	Abstract Reviewer	Yes	Abbott Medical: Advisory Board Member
Louer, Craig	Co-Author	Yes	Depuy Synthes Spine: Consultant; Globus Medical: Research Grant; National Scoliosis Clinics: Advisory Board Member
Maguiness, Sheilagh	Faculty	Yes	Stryke Club: Employee/Owner
Major-Kincade, Terri	Faculty	Yes	Proctor and Gamble: Advisory Board Member
M Schwend, Richard	Senior Author	Yes	Orthopediatrics Company: Consultant; Orthopediatrics Foundation: Principal Investigator
Mardjetko, Steven	Abstract Reviewer	Yes	Spinecraft Corporation: Advisory Board Member, Board of Directors, Stockholder
Martin-Blais, Rachel	Abstract Reviewer	Yes	Citius Pharmaceuticals: Stockholder; Fate Therapeutics: Stockholder; General Electric: Stockholder; Merck: Stockholder; Organon: Stockholder

DISCLOSURE OF FINANCIAL RELATIONSHIPS

All individuals in a position to influence and/or control the content of AAP CME activities are required to disclose to the AAP and subsequently to learners that the individual either has no financial relationships or any financial relationships with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in CME activities. An ineligible company is defined as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Listed below are the disclosures provided by individuals in a position to influence and/or control CME activity content. **All of the relevant financial relationships listed for these individuals have been mitigated.** This activity may discuss or demonstrate pharmaceuticals and/or medical devices that are not approved by the FDA and/or medical or surgical procedures that involve an unapproved or "off-label" use of an approved device or pharmaceutical.

All other faculty, planners and staff have reported no financial relationships with ineligible companies.

Name	Role	Any Financial Relationships (Please indicate Yes or No)	Name of Ineligible Company* Please list name(s) of entity AND Nature of Financial Relationship(s) (Please list: Research Grant, Speaker's Bureau, Stock/Bonds excluding mutual funds, Consultant, Other - identify)
Martinez-Gonzalez, Karen	Co-Author	Yes	Abbvie: Consultant, Sage pharmaceuticals: Consultant
Mason, Mathew	Co-Author	Yes	Merck: Consultant
May, Collin	Senior Author	Yes	Orthopediatrics: Consultant; Wishbone Medical: Consultant
McCrinkle, Brian	Co-Author	Yes	Amryt Pharma: Consultant; Chiesis: Consultant; Esperion: Consultant; Ultragenyx: Advisory Board Member
McIntosh, Amy	Co-Author	Yes	Globus Medical: Advisory Board Member
Merchant, Nadia	Faculty	Yes	Pfizer: Advisory Board Member; BioMarin: Advisory Board Member; Alexion: Advisory Board Member; Catalyst: Advisory Board Member
Millbrandt, Todd	Faculty	Yes	Medtronic: Consultant; Pathkeeper: Consultant; Depuy Spine: Consultant; Nsite: Consultant; Viking Scientific: Stockholder
Modi, Biren	Senior Author, Abstract Reviewer	Yes	Vertex Pharmaceuticals: Stockholder
Mokshagundam, Deepa	Abstract Reviewer	Yes	Berlin Heart: Research Grant; CareDx: Research Grant
Molina-Molina, Emilio	Co-Author	Yes	Abbott Laboratories: Employee/Owner
Moore, Lindsey	Faculty	Yes	Aimmune: Speaker Bureau; Kenota Health: Principal Investigator; Evidera: Consultant; Genentech: Speaker Bureau
Murali, Chaya	Co-Author	Yes	Biomarin Pharmaceuticals: Research Grant
Neal, Kevin	Abstract Reviewer	Yes	OrthoPediatrics: Consultant
Newburger, Jane	Co-Author	Yes	Bristol-Myers Squibb: Honorarium, Principal Investigator; Merck: Honorarium; Pfizer Inc: Research Grant
Newland, Jason	Faculty	Yes	Pfizer: Principal Investigator; Moderna: Principal Investigator
Nischal, Kanwal	Co-Author	Yes	ESSILOR: Research Grant; Graybug: Consultant; KRYSTAL: Consultant; OCUMENSION: Research Grant; SANTEN: Honorarium
Nuchtern, Jed	Co-Author	Yes	Intuitive Surgical, Inc: Stockholder, Johnson and Johnson, Inc: Stockholder
Nykanen, David	Co-Author	Yes	Abbott Medical: Consultant; Baylis Medical: Consultant; Renata Medical: Consultant; W.L Gore and Associates: Consultant
Olutoye, Oluyinka	Senior Author	Yes	Mallinkrodt: Principal Investigator, Research Grant; Medtronic: Principal Investigator, Research Grant
Owen, Jonas	Co-Author	Yes	OrthoPediatrics: Consultant
Pacicca, Donna	Abstract Reviewer	Yes	Medtronic: Stockholder; Zimmer Biomet: Stockholder
Padilla, Benjamin	Senior Author	Yes	Atricure: Consultant

DISCLOSURE OF FINANCIAL RELATIONSHIPS

All individuals in a position to influence and/or control the content of AAP CME activities are required to disclose to the AAP and subsequently to learners that the individual either has no financial relationships or any financial relationships with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in CME activities. An ineligible company is defined as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Listed below are the disclosures provided by individuals in a position to influence and/or control CME activity content. **All of the relevant financial relationships listed for these individuals have been mitigated.** This activity may discuss or demonstrate pharmaceuticals and/or medical devices that are not approved by the FDA and/or medical or surgical procedures that involve an unapproved or "off-label" use of an approved device or pharmaceutical.

All other faculty, planners and staff have reported no financial relationships with ineligible companies.

Name	Role	Any Financial Relationships (Please indicate Yes or No)	Name of Ineligible Company* Please list name(s) of entity AND Nature of Financial Relationship(s) (Please list: Research Grant, Speaker's Bureau, Stock/Bonds excluding mutual funds, Consultant, Other - identify)
Pal, Anandita	Faculty	Yes	Sanofi: Consultant; Pampers: Consultant; Aveeno: Consultant; Buzz Rx: Consultant; Vanicream: Consultant; Kabrita: Advisory Board Member; Nozebot: Consultant; Milk Pep: Consultant; Duracell: Consultant; GMAC: Consultant
Parsi, Linda	Faculty	Yes	Mead Johnson: Speaker Bureau
Patel, Ravi	Abstract Reviewer	Yes	Infant Bacterial Therapeutics / Premier Research: Serve on DMC, Noveome: Consultant
Peltier, Christopher	Faculty	Yes	Procter and Gamble: Advisory Board Member; Mead Johnson: Speaker Bureau; By Heart: Research Grant; GSK: Research Grant; Danone Nutrica: Research Grant
Perman, Marissa	Faculty	Yes	Abeona: Consultant; Aegle: Principal Investigator
Petrikin, Josh	Abstract Reviewer	Yes	Abbott Nutrition: Speaker Bureau
Pilcher, Thomas	Co-Author	Yes	Abbott: Speaker Bureau
Pramanik, Arun	Abstract Reviewer	Yes	Chiesi Inc.: Speaker Bureau
Prince, Benjamin	Faculty	Yes	Sanofi: Advisory Board Member
Puder, Mark	Senior Author	Yes	Northsea Pharma: Advisory Board Member, Research Grant; Northsea Therapeutics: Advisory Board Member, Research Grant
Purves, Todd	Faculty	Yes	Abbvie: Principal Investigator; ExstoBio inc: Advisory Board Member
Ramsey, Nicole	Faculty	Yes	Pfizer Pharmaceuticals: Principal Investigator
Raynor, Eileen	Faculty	Yes	Inspire Medical: Principal Investigator
Reed, Jennifer	Abstract Reviewer	Yes	Becton Dickinson: Stockholder; CVS Caremark: Stockholder; Danahar: Stockholder; Intuitive Surgical: Stockholder; Stryker: Stockholder; Thermo Fisher Scientific: Stockholder; United Health Group: Stockholder
Richards-Kortum, Rebecca	Co-Author	Yes	3rd Stone Design: Research Grant
Rigotti, Nancy	Co-Author	Yes	Achieve Life Sciences: Consultant, Principal Investigator, Research Grant
Rizzo, Christopher	Abstract Reviewer	Yes	Sanofi: Employee/Owner
Robinson, Marie-Eve	Co-Author	Yes	Ascendis Biopharma and Ipsen Biopharmaceuticals: Research grant; Ultragenyx and Ipsen Biopharmaceuticals: Consultant, Research Grant
Rosbe, Kristina	Teaching Assistant	Yes	Boston Scientific: Stockholder, Merck: Stockholder, Pfizer: Stockholder
Ross, Kirsten	Faculty	Yes	Johnson & Johnson: Consultant; Medtronic: Consultant

DISCLOSURE OF FINANCIAL RELATIONSHIPS

All individuals in a position to influence and/or control the content of AAP CME activities are required to disclose to the AAP and subsequently to learners that the individual either has no financial relationships or any financial relationships with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in CME activities. An ineligible company is defined as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Listed below are the disclosures provided by individuals in a position to influence and/or control CME activity content. **All of the relevant financial relationships listed for these individuals have been mitigated.** This activity may discuss or demonstrate pharmaceuticals and/or medical devices that are not approved by the FDA and/or medical or surgical procedures that involve an unapproved or "off-label" use of an approved device or pharmaceutical.

All other faculty, planners and staff have reported no financial relationships with ineligible companies.

Name	Role	Any Financial Relationships (Please indicate Yes or No)	Name of Ineligible Company* Please list name(s) of entity AND Nature of Financial Relationship(s) (Please list: Research Grant, Speaker's Bureau, Stock/Bonds excluding mutual funds, Consultant, Other - identify)
Rossano, Joseph	Moderator, Abstract Reviewer	Yes	American Regent: Consultant; AskBio: Consultant; BioMarin: Consultant; Bayer: Consultant; Bristol Myers Squibb: Consultant; Enzyvant: Consultant
Rubinstein Reiss, Dorit	Faculty	Yes	GSK: Stockholder
Sanders, Julia	Co-Author	Yes	OrthoPediatrics: Consultant
Sankar, Wudbhav	Co-Author	Yes	Medivir: Consultant; OrthoPediatrics: Consultant
Sathanandam, Shyam	Co-Author	Yes	Abbott: Consultant, Research Grant, Speaker Bureau; Cannon: Research Grant, Speaker Bureau; Medtronic: Consultant, Research Grant; Penumbra: Speaker Bureau
Schmitz, Jonathan	Faculty	Yes	Biofire / Biomereix: Research Grant; Genmark / Roche: Research Grant; SASR Health: Research Grant; Quantum Materials Corporation; Research Grant; Karius Diagnostics: Research Grant, Grant; OM-1/Hologic: Research Grant
Schulz, Jacob	Co-Author	Yes	Johnson and Johnson: Consultant; Orthopediatrics: Consultant
Schwend, Richard	Abstract Reviewer	Yes	Orthopediatrics Company: Consultant
Scottoline, Brian	Abstract Reviewer	Yes	Infinant Health: Principal Investigator
Secord, Elizabeth	Co-Author	Yes	Gilead: Co-Investigator; ViiV: Principal Investigator
Sekhar, Deepa	Abstract Reviewer	Yes	American Kidney Stone Management: Stockholder, United Medical Systems: Stockholder
Shahanavaz, Shabana	Co-Author	Yes	Edwards Lifesciences: Consultant
Sharn, Amy	Presenting Author	Yes	Abbott Nutrition: Employee/Owner
Siddiqui, Sabina	Abstract Reviewer	Yes	Brio Device, LLC: Research Grant, Stockholder
Smith, John	Co-Author	Yes	Globus: Consultant
Smith, Michael	Abstract Reviewer	Yes	Pfizer: Research Grant
Snyder, Brian	Co-Author	Yes	Alcyone: Consultant; OrthoPediatric: Consultant
Soghier, Lamia	Faculty	Yes	Pyrames: Principal Investigator; Etiometry: Principal Investigator
Sohl, Kristin	Faculty	Yes	Cognoa: Research Grant; Quadrant Biosciences: Advisory Board Member
Song, Clara	Faculty, Abstract Reviewer	Yes	Mead Johnson Nutrition: Speaker Bureau
Soslow, Jonathan	Faculty	Yes	Pfizer: Consultant; Sarepta: Consultant; Immunoforge: Consultant, WCG: Consultant

DISCLOSURE OF FINANCIAL RELATIONSHIPS

All individuals in a position to influence and/or control the content of AAP CME activities are required to disclose to the AAP and subsequently to learners that the individual either has no financial relationships or any financial relationships with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in CME activities. An ineligible company is defined as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Listed below are the disclosures provided by individuals in a position to influence and/or control CME activity content. **All of the relevant financial relationships listed for these individuals have been mitigated.** This activity may discuss or demonstrate pharmaceuticals and/or medical devices that are not approved by the FDA and/or medical or surgical procedures that involve an unapproved or "off-label" use of an approved device or pharmaceutical.

All other faculty, planners and staff have reported no financial relationships with ineligible companies.

Name	Role	Any Financial Relationships (Please indicate Yes or No)	Name of Ineligible Company* Please list name(s) of entity AND Nature of Financial Relationship(s) (Please list: Research Grant, Speaker's Bureau, Stock/Bonds excluding mutual funds, Consultant, Other - identify)
Spinner, Joseph	Faculty	Yes	Enduring Hearts: Research Grant; Bristol Myers Squibb: Principal Investigator; Cobicure: Consultant; Enzyvant: Consultant
Stephens-Shields, Alisa	Co-Author	Yes	Gilead Sciences: Consultant
Stetson, Raymond	Senior Author	Yes	Moderna: Research Grant
Storch, Eric	Senior Author	Yes	Biohaven: Consultant
Strominger, Mitchell	Faculty	Yes	Amgen: Speaker Bureau
Stukus, David	Faculty	Yes	ARS Pharmaceuticals: Consultant; DBV Technologies: Principal Investigator
Sulo, Suela	Co-Author	Yes	Abbott: Employee/Owner
Sumpter, Kathryn	Co-Author	Yes	Becton Dickinson: Stockholder; Boston Scientific: Stockholder; Eli Lilly: Stockholder; HCA Healthcare: Stockholder; Medtronic: Stockholder; Thermo Fisher Scientific: Stockholder
Swanson, Jonathan	Abstract Reviewer	Yes	Prolacta Bioscience, Inc: Speaker Bureau
Tandon, Animesh	Abstract Reviewer	Yes	Eli Lilly: Stockholder; Gabi Smartcare: Consultant; Medtronic: Consultant; Moderna: Stockholder; Novo Nordisc: Stockholder; Siemens Healthineers: Consultant; Synergen Health Technologies: Consultant; Vertex Pharmaceuticals: Stockholder; Viking Therapeutics: Stockholder
Thayer, Jeritt	Co-Author	Yes	HealthChart: Stockholder
Tong, Carmen	Faculty	Yes	Novo Nordisk: Advisory Board Member
Travers, Colm	Abstract Reviewer	Yes	Owlet Baby Care Inc.: Research Grant
Tsikis, Savas	Co-Author	Yes	Alcresta Therapeutics: Consultant
Turek, Joseph	Faculty	Yes	Surge Ingenuity Corp: Stockholder
Tyler, Amy	Faculty	Yes	Biomerieux: Stockholder
Upasani, Vidyadhar	Co-Author	Yes	Daedalus Medical Solutions, Inc.: Employee/Owner; DePuy, A Johnson & Johnson Company: Consultant; Imagen: Stockholder; OrthoPediatics: Consultant; Pacira: Consultant; Stryker: Consultant
Valentine, Gregory	Abstract Reviewer	Yes	Equicare Solutions LLC: Consultant, Equicare Solutions LLC: Principal Investigator
Vergales, Jeffrey	Abstract Reviewer	Yes	Locus Health: Consultant
Vitale, Michael	Co-Author	Yes	Stryker Spine: Consultant; Zim Vie Spine: Consultant
Walley, Susan	Abstract Reviewer	Yes	Atea Pharmaceuticals: Stockholder; Gilead Sciences, Inc: Stockholder
Wang, Julie	Faculty	Yes	Aimmune Therapeutics: Research Grant; DBV Technologies: Research Grant; Siolta: Research Grant; Regeneron: Research Grant; ALK Abello: DSMB member; Jubilant HollisterStier: Consultant
Weems, Mark	Faculty	Yes	Abbott Congenital Heart: Speaker Bureau

DISCLOSURE OF FINANCIAL RELATIONSHIPS

All individuals in a position to influence and/or control the content of AAP CME activities are required to disclose to the AAP and subsequently to learners that the individual either has no financial relationships or any financial relationships with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in CME activities. An ineligible company is defined as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Listed below are the disclosures provided by individuals in a position to influence and/or control CME activity content. **All of the relevant financial relationships listed for these individuals have been mitigated.** *This activity may discuss or demonstrate pharmaceuticals and/or medical devices that are not approved by the FDA and/or medical or surgical procedures that involve an unapproved or "off-label" use of an approved device or pharmaceutical.*

All other faculty, planners and staff have reported no financial relationships with ineligible companies.

Name	Role	Any Financial Relationships (Please indicate that are not approved by the FDA and/or medical or surgical procedures that involve an unapproved or "off-label" use of an approved device or pharmaceutical.)	Name of Ineligible Company* Please list name(s) of entity AND Nature of Financial Relationship(s) (Please list: Research Grant, Speaker's Bureau, Stock/Bonds excluding mutual funds, Consultant, Other - identify)
Whitaker, Amanda	Senior Author	Yes	Pacira: Advisory Board Member
Wilson, Philip	Senior Author	Yes	AlloSource: Research Support
Wimmer, Sam	Co-Author	Yes	Johnson & Johnson: Stockholder
Yaszay, Burt	Co-Author	Yes	Depuy Synthes: Consultant; Globus: Consultant; Medtronic: Consultant; Nuvasive: Consultant; Orthopediatrics: Consultant; Pacira: Consultant; Stryker: Consultant
Yen, Yi-Meng	AAP Section/Council Program Chair	Yes	Smith-Nephew: Consultant
Yoo, Sylvia	Faculty	Yes	Sydnexis: Principal Investigator; Doximity: Stockholder
Zampi, Jeffrey	Co-Author	Yes	Encore Medical: Advisory Board Member; Gore Medical: Consultant; Medtronic Inc: Consultant